Ergoteles LLC Ascendis Pharma A/S Transaction History

Ergoteles LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$69.96 - $97.84 $472,160 - $660,322	6,749 Added 99.81%	13,511 $1.21 Million
Q1 2023 May 10, 2023	BUY	$104.9 - $126.78 $219,765 - $265,604	2,095 Added 44.89%	6,762 $725,000
Q4 2022 Feb 14, 2023	BUY	$99.42 - $131.97 $221,905 - $294,557	2,232 Added 91.66%	4,667 $569,000
Q3 2022 Nov 14, 2022	BUY	$84.03 - $110.23 $16,301 - $21,384	194 Added 8.66%	2,435 $251,000
Q2 2022 Aug 12, 2022	BUY	$78.08 - $117.61 $174,977 - $263,564	2,241 New	2,241 $208,000
Q1 2022 May 13, 2022	SELL	$102.18 - $135.75 $1.35 Million - $1.79 Million	-13,165 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$127.1 - $169.66 $1.67 Million - $2.23 Million	13,165 New	13,165 $1.77 Million
Q2 2021 Aug 12, 2021	SELL	$121.62 - $145.29 $2.26 Million - $2.69 Million	-18,547 Closed	0 $0
Q1 2021 May 12, 2021	BUY	$124.92 - $173.33 $2.32 Million - $3.21 Million	18,547 New	18,547 $2.39 Million

244

58.8M

250K

377K

Ticker ASND
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,810,200
Market Cap $7.61B
Description
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...

Get notified when there are updates to the investment portfolio of Ergoteles LLC, based on Form 13F filings with the SEC.

Stay updated on Ergoteles LLC with notifications on news.